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the  TERT core promoter (–260 to +60) was analyzed by direct 
Sanger sequencing or SNaPshot analysis.  Results: All cases 
were analyzed successfully. Mutations within the core pro-
moter of the  TERT gene were not detected in any of the cas-
es with all tumors exhibiting a wild-type sequence.  Conclu-
sion:  TERT core promoter mutations reported from several 
other malignancies were not detected in our unselected co-
hort of PrCa. These data indicate that alterations within the 
core promoter of the  TERT gene do not play an important 
role in prostate carcinogenesis.  © 2015 S. Karger AG, Basel 
 Introduction 
 The search for recurrent mutations in single genes 
within tumor genomes is driven by the hope of uncover-
ing important driver alterations that lead to a better un-
derstanding of carcinogenesis. The availability of new 
and sensitive high-throughput sequencing technologies 
sped up this search and led to the identification of new 
mutation hotspots in a variety of cancer entities. Al-
though a new definition of a recurrent gene mutation was 
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 Abstract 
 Objective: Recently, recurrent mutations within the core 
promoter of the human telomerase reverse transcriptase 
 (TERT) gene generating consensus binding sites for ETS tran-
scription factor family members were described in melano-
mas and other malignancies (e.g. bladder cancer, hepatocel-
lular carcinoma). These mutations were discussed as early 
drivers for malignant transformation. In prostate cancer 
(PrCa) TERT expression has been associated with a poor 
prognosis and higher risk for disease recurrence. The under-
lying mechanisms for high  TERT expression in PrCa have still 
not been clarified. To date, data on  TERT promoter mutation 
analysis in PrCa are sparse. Therefore, we performed se-
quence analysis of the core promoter region of the  TERT 
gene in an unselected cohort of prostate tumors.  Methods: 
Sections from 167 formalin-fixed, paraffin-embedded and 
cryopreserved prostate tumors were microdissected and 
used for DNA isolation. The mutation hotspot region within 
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suggested in terms of combining recurrent alterations on 
the scale of a pathway rather than only one single gene, 
discovering new recurrent gene mutations is still a worth-
while approach in cancer research  [1] .
 Recently, mutations within the promoter of the telom-
erase reverse transcriptase  (TERT) gene that encodes the 
catalytic subunit of the telomerase were identified in fa-
milial and sporadic melanoma with a high frequency  [2] . 
The immortality of cells is still a classical hallmark of tu-
mors and reactivation of telomerase leading to telomere 
maintenance remains a fundamental process in carcino-
genesis. Alterations within the coding region of the  TERT 
gene are a rare event in cancers. Therefore, the identifica-
tion of recurrent mutations within the core promoter of 
the  TERT gene leading to new binding motifs for tran-
scription factors of the ETS family attracted great interest 
among the cancer research field  [3] . The consequences of 
these mutations are still not completely understood but 
they lead to a 2- to 4-fold increased transcriptional activ-
ity in vitro  [4] . Subsequently, these mutations were found 
in several other malignancies, e.g. bladder carcinoma, 
thyroid cancer or cancers of the nervous system, and were 
discussed as early drivers for malignant transformation 
 [3] . 
 Expression and reactivation of telomerase has also 
been described as an important feature of prostate cancer 
(PrCa). Telomerase activity was found in up to 100% of 
analyzed PrCa cases  [5] . Interestingly, high expression of 
telomerase components does not always result in manda-
tory telomerase activity  [6] . In addition, a significant as-
sociation between  TERT expression and aggressive be-
havior of prostate tumors has been reported  [7] . Recently, 
promising in vitro data were published showing telomer-
ase as an important target of an antiandrogen therapy for 
PrCa, and the usefulness of boron derivatives as a telom-
erase inhibitor in PrCa cells  [8, 9] . These data suggest 
telomerase inhibition as a reasonable therapeutic ap-
proach for the treatment of PrCa. The molecular and cel-
lular pathways involved in telomerase reactivation in 
PrCa are still not clear. Expression of  TERT and the activ-
ity of telomerase were shown to be regulated by androgen 
receptor (AR) signaling whereas exogenous expression of 
AR surprisingly led to inhibition of  TERT transcription 
in PrCa cells  [10, 11] . The genomic region of the  TERT 
gene (chromosome 5p15.33) was not described as a re-
gion containing copy number alterations in prostate tu-
mors, making gene amplification as a mechanism for 
 TERT expression in PrCa unlikely  [12] . Less is known 
about  TERT promoter mutations in PrCa. To date only 
three studies with a combined number of 49 prostate tu-
mors have reported sequence analysis of the  TERT pro-
moter and found no evidence for involvement of  TERT 
promoter mutations in PrCa  [13–15] . These data already 
indicate that the cellular mechanisms of telomerase reac-
tivation in PrCa are only poorly understood and further 
clarification is needed. As  TERT promoter mutations are 
a potential mechanism for a possible telomerase reactiva-
tion we wanted to further the discussion of this topic for 
PrCa. We therefore analyzed the core promoter region of 
the  TERT gene containing the reported mutation hotspots 
in the largest series of PrCa examined to date.
 Materials and Methods 
 Patients and Tissue Samples 
 Overall, 167 unselected, archival prostate tumors (formalin-
fixed and paraffin-embedded tissue samples, n = 119; snap-frozen 
tissue samples, n = 48) were investigated. All patients were Cauca-
sians. The tumors were diagnosed according to the WHO classifi-
cation of prostate tumors and staged according to the TNM system 
 [16, 17] . The characteristics of the study participants are shown in 
 table  1 . Prior institutional review board (University Hospital 
 Erlangen) approval was obtained for molecular analysis on archi-
val material.
 Tissue Microdissection and DNA Isolation 
 DNA was extracted from prostate tumors after precise manual 
microdissection (purity of tumor cells >85%) of serial sections 
(5 μm) using the High Pure PCR Template Preparation Kit (Roche 
GmbH, Mannheim, Germany) according to the manufacturer’s 
instructions. DNA quality and quantity was determined using the 
Synergy 2 Multi-Detection Reader (BioTek, Bad Friedrichshall, 
Germany) according to the manufacturer’s instructions.
 Table 1.  Characteristics of the study patients
PrCa cases, n
Age, years
Range
Median
167
46–87
66
Mean 64.9±6.7
Stage, n 
Organ-confined disease
Non-organ-confined disease
No data available
76
89
2
Gleason score
Range
Median
3–10
7
Gleason sum, n
<7
7
>7
No data available
52
54
54
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 TERT Promoter Analysis Using Sanger Sequencing 
 A region of the core promoter (–260 to +60) of the  TERT gene 
containing the described mutation hotspots was amplified by 
PCR using primers (sense: 5 ′ - att cgc ggg cac aga cgc -3 ′ ; anti-
sense: 5 ′ - tcg cgg tag tgg ctg cgc -3 ′ ) obtained from Metabion 
(Martinsried, Germany) in a total volume of 25 μl containing ap-
proximately 150 ng DNA, 0.2 m M dNTP (Promega, Mannheim, 
Germany), 0.18 μ M primers, 5% DMSO and 0.0025 U/μl GoTaq 
(Promega). The thermal cycling conditions were as follows: ini-
tial denaturation for 3 min at 95   °   C, 45 cycles of denaturation at 
94  °  C for 1 min, annealing at 69.3  °  C for 1 min, elongation at 72  °  C 
for 1 min and final primer extension at 72   °   C for 10 min. Gradi-
ent PCR was used for the optimization of cycling conditions. Af-
ter amplification, PCR products (size 335 bp) were purified using 
the Qiagen Dye Ex 2.0 TM Spin Kit according to the manufacturer’s 
conditions. Sequence analysis was performed with PCR primers 
using a Big Dye Terminator v.1.1 Cycle Sequencing Kit and an 
ABI 3500 Genetic Analyzer (both Applied Biosystems, Foster 
City, Calif., USA). 
 TERT Promoter Analysis Using SNaPshot Analysis 
 A previously reported SNaPshot assay (Life Technologies 
Corp., Carlsbad, Calif., USA) was used for the detection of hotspot 
mutations at positions –57, –124 and –146. Capillary electropho-
resis and detection of fluorescence-labeled products were per-
formed using an Applied Biosystems ABI 3500 Genetic Analyz-
er. A detailed description of the method can be found elsewhere 
 [18] .
 Cell Lines Used as Positive Controls for TERT Mutation 
Analysis 
 The malignant melanoma cell line SK-MEL28 derived form 
a 51-year-old male patient was kindly donated by Prof. Dr. A. 
Bosserhoff (Institute of Biochemistry and Molecular Medicine, 
FAU Erlangen-Nuremberg, Germany). SK-MEL28 cells showed 
a –57 A  → C mutation of the  TERT promoter. The urothelial car-
cinoma cell line RT112 derived from a female patient with a 
transitional cell carcinoma of the urinary bladder was pur-
chased from the German collection of microorganisms and cell 
cultures (Leibniz Institute DMSZ, Braunschweig, Germany). 
RT112 cells harbor a –124 C  → T mutation of the  TERT promot-
er  [4] . 
 Results 
 Analysis of previously reported mutation hotspots 
within the core promoter of the  TERT gene was success-
fully performed in all available cases. Mutation analysis 
using Sanger sequencing could be performed in 108/167 
cases ( fig. 1 ). In 59/167 cases the core promoter region 
could not be amplified due to insufficient DNA quality 
(e.g. DNA degradation, low DNA concentration). In 
these cases SNaPshot analysis of mutation sites at –57, 
 Fig. 1. Representative examples for Sanger sequencing and 
SNaPshot analysis of the promoter mutation hotspots at –57 and 
–124. Upper lane: Sanger sequencing of DNA from a prostate 
tumor showing a wild-type sequence for  TERT promoter posi-
tion –57 (A) and position –124 (G). DNA from the melanoma 
cell line  SK-MEL-28 showing ‘A  → C’ mutation at position –57. 
DNA from the bladder cancer cell line RT112 showing ‘G  → A’ 
mutation at position –124. Lower lane: corresponding SNaPshot 
analyses. Arrows indicate mutations in the promoter sequence.  
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–124 and –146 was performed ( fig. 1 ). Promoter muta-
tions were not detected in any of the samples with all cas-
es exhibiting a wild-type sequence.
 Discussion 
 In the present study we performed sequence analysis 
of the core promoter region of the  TERT gene in a cohort 
of 167 PrCa samples. The results of our study suggest that 
 TERT promoter mutations are not involved in the devel-
opment of PrCa as no mutations were detected in any of 
the investigated cases. These data are in line with previ-
ously published studies on only very small cohorts and 
corroborate the minor importance of  TERT promoter al-
terations in PrCa  [13–15] . Meanwhile, a study investigat-
ing the whole genomes of 57 PrCa cases has been pub-
lished  [19] . Apart from already known data from exome 
analyses, this study displayed the spectrum of whole-ge-
nome alterations in prostate tumors. Here only one  TERT 
missense mutation was detected (p.R819C) but no pro-
moter mutations were reported. This study also strength-
ens our findings and should, together with our data, final-
ize the discussion on  TERT mutations in PrCa.
 There are several lines of evidence that genomic vari-
ations but not mutation might influence TERT expres-
sion and disease risk in PrCa. In a large case-control 
study an intronic single nucleotide polymorphism (SNP) 
in the  TERT gene (rs2242652, C 8992 T) was found that 
was strongly associated with increased PrCa risk. Be-
cause of this strong correlation it was suggested that the 
SNP might have a functional relevance. Indeed, further 
evaluation showed increased TERT expression associat-
ed with the presence of SNP variants in benign prostate 
tissue from patients who underwent radical prostatec-
tomy  [20, 21] . This increased TERT expression might 
provide a possible predisposition for PrCa. Another in-
fluence on  TERT expression might be length polymor-
phisms in variable number tandem repeats (VNTRs). 
Recently, it was shown that the  TERT gene contains five 
VNTRs that are located within introns 2 and 6. A large 
case-control study found a significantly higher PrCa risk 
for individuals carrying rare VNTR2-2nd alleles than for 
individuals with common alleles. These VNTRs were 
also discussed as having an enhancer function for gene 
transcription. In vitro studies on PrCa cell lines analyz-
ing the activity of the  TERT promoter in combination 
with different VNTR variants clearly showed an in-
creased luciferase activity for the VNTR2-2nd variants 
 [22, 23] . These effects might also be expected for  TERT 
expression and could also increase the individual risk for 
PrCa. 
 Besides these genomic influences, TERT expression is 
also regulated by several cellular processes in PrCa. Mat-
sumura et al.  [24] analyzed the impact of the phosphory-
lation status of Fas-associated death domain-containing 
protein (FADD) on TERT expression in PrCa. FADD has 
a crucial role in the formation of the death-inducing sig-
naling complex and is also involved in cell cycle regula-
tion. The phosphorylated form of FADD was highly ex-
pressed in PrCa with a lower Gleason score and was in-
versely associated with a shorter recurrence-free survival 
after prostatectomy. In parallel, cases with high levels of 
phosphorylated FADD also showed only low TERT ex-
pression, suggesting a direct influence of FADD phos-
phorylation on TERT expression. Shimada et al.  [25] 
found significant differences between FADD phosphory-
lation levels and clinicopathological outcomes for Glea-
son scores 3 + 4 and 4 + 3. These data indicate that Glea-
son 4 + 3 tumors should be considered as high-risk tu-
mors and stimulating agents that drive transition from 
nonphosphorylated to phosphorylated FADD (e.g. pacli-
taxel) might be considered as therapeutic options. High 
TERT expression correlates with aggressive PrCa levels of 
TERT and nonphosphorylated FADD, which might rep-
resent potent biomarkers for the biological behavior of 
PrCa. Furthermore, different factors can regulate TERT 
expression positively or negatively. Several transcription 
factors (e.g. SP1), hormones (e.g. androgen) and the 
PI3K/Akt and MAP kinase pathways can upregulate 
 TERT transcription [reviewed in  26 ]. In addition, the 
downregulation of  TERT by six microRNAs (let-7g * , 
miR-133a, miR-138–5p, miR-342–5p, miR-491–5p and 
miR-541–3p) has recently been reported  [27] .
 In summary, high expression of  TERT is unlikely to be 
caused by promoter mutations or other genomic altera-
tions in PrCa.  TERT expression is more likely influenced 
by diverse cellular pathways resulting in increased cell 
cycle activity and proliferation.
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